2025年発表論文

2025.11.25

2025年に当教室で発表した和文論文です。

題名（論文名）	著者	掲載雑誌
泌尿器科領域周術期感染症と合併症　ガイドラインからみえる未来予想図．周術期の手術部位感染症予防のための術中処置．	重原一慶，溝上敦．	臨床泌尿器科2025; 79(11): 948-954．
男性におけるHPV感染症～今、どこまで分かっているのか？～	重原一慶，溝上敦．	臨床とウイルス2025．53巻（in press）
【難治性前立腺癌と戦う-希少型前立腺癌・薬剤耐性癌の最新の話題とゲノムプロファイル-】ダブルネガティブ去勢抵抗性前立腺癌の最新の話題とゲノムプロファイル	泉浩二, 神島泰樹, 溝上敦.	Prostate Journal 2025; 12(2): 127-133.
ARに制御されるmiRNA-124-3p.2は転移促進因子CCL2を抑制する	青山周平, 泉浩二, 溝上敦	泌尿器外科 2025; 38(8): 833-835.
【前立腺癌の診断および治療選択にかかわる最新知識】従来型画像診断　骨シンチグラフィを中心に	溝上　敦	Prostate Journal 2025; 12(1): 49-54.
【mCSPC Deep Field】CAB療法の再評価　日本独自の進展	溝上　敦	泌尿器外科 2025; 38(4): 317-323.
【これだけは押さえておきたい　がん薬物療法の薬　抗がん薬　ホルモン剤　分子標的薬　免疫チェックポイント阻害薬　はや調べノート　2025　2026年版】分子標的薬　PARP阻害薬　タラゾパリブ	泉浩二	YORi-SOUがんナーシング2025春季増刊：233-234
【今のうちにしっかり理解　最新の前立腺癌診療と近未来予想図】診断と治療　PSMA-PETとPSMA-RLTを用いた前立腺癌の診断と治療	泉浩二	臨床泌尿器科 2025; 79(1): 82-87

2025年に当教室の医局員が発表した英文論文です（ 12月14 日現在）

題名（論文名）	著者	掲載雑誌
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.	Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A.	Prostate. 2025; 85(1):21-29.
Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis.	Nakagawa R, Izumi K, Hiratsuka K, Inaba T, Koketsu Y, Toriumi R, Aoyama S, Kamijima T, Kano H, Makino T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Nakata H, Lin WJ, Mizokami A.	Neoplasia. 2025 Feb: 60:101103.
Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?	Naito R, Izumi K, Takimoto A, Nakagawa R, Kano H, Makino T, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A.	Int J Urol. 2025; 32(7):830-838.
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.	Okamura T, Izumi K, Kurokawa S, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A.	Prostate. 2025; 85(10):903-911.
Androgen Receptor-Controlled microRNA-124-3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition.	Aoyama S, Izumi K, Hiratsuka K, Inaba T, Koketsu Y, Nakagawa R, Toriumi R, Kamijima T, Kano H, Makino T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Nakata H, Saito Y, Nakagawa-Goto K, Lin WJ, Mizokami A.	Cancer Sci. 2025; 116(10):2797-2807.
Association Between Preoperative 5-Aminolevulinic Acid Administration Timing and Perioperative Hypotension.	Hori T, Nohara T, Kawahara T, Nakagawa R, Fukuda R, Kamijima T, Kano H, Makino T, Naito R, Iwamoto H, Yaegashi H, Shigehara K, Izumi K, Mizokami A.	Int J Urol. 2025; 32(12):1827-1833.
Effect of androgen deprivation therapy after radical prostatectomy on urinary symptoms.	Kawaguchi S, Shigehara K, Kadono Y, Kato Y, Kano H, Makino T, Naito R, Iwamoto H, Yaegashi H, Nohara T, Izumi K, Mizokami A.	Urologia. 2025; 92(2):329-334.
Testosterone Replacement Therapy Can Improve a Biomarker of Liver Fibrosis in Hypogonadal Men: A Subanalysis of a Prospective Randomized Controlled Study in Japan (EARTH Study).	Shigehara K, Kato Y, Shinzawa R, Konaka H, Kawaguchi S, Nohara T, Izumi K, Namiki M, Mizokami A.	World J Mens Health. 2025; 43(3):661-668.
Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy.	Shigehara K, Naito R, Kawahara T, Kato Y, Shinzawa R, Yaegshi H, Nohara T, Izumi K, Mizokami A.	Cureus. 2025; 17(9):e92806.
Comprehensive Genome Profiling Test in Japanese Patients With Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.	Hori T, Iwamoto H, Makino T, Naito R, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Izumi K, Mizokami A.	Cureus. 2025; 17(1):e77300.
Biochemical response to neoadjuvant hormonal therapy predicts long-term prostate cancer survival outcomes after high-dose-rate brachytherapy with external beam radiotherapy.	Makino T, Sakurai T, Takamatsu S, Kano H, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Izumi K, Mizokami A.	Sci Rep. 2025;15(1):5118.
Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer.	Makino T, Sakurai T, Takamatsu S, Nakagawa R, Kamijima T, Kano H, Naito R, Iwamoto H, Yaegashi H, Shigehara K, Nohara T, Izumi K, Mizokami A.	Cancers (Basel). 2025; 17(19):3151.
Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.	Iwamoto H, Hori T, Inaba T, Nakagawa R, Kamijima T, Kano H, Makino T, Naito R, Yaegashi H, Nohara T, Shigehara K, Izumi K, Mizokami A.	Int J Urol. 2025; 32(11):1640-1649.
Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population.	Nakagawa R, Naito R, Izumi K, Inaba T, Toriumi R, Aoyama S, Kamijima T, Kano H, Makino T, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Mizokami A.	Asia Pac J Clin Oncol. 2025 Nov 11. doi: 10.1111/ajco.70051.
Human Papillomavirus Prevalence in the Prostate and Seminal Vesicles: Does This Virus Have an Etiological Role in the Development of Prostate Cancer?	Shinzawa R, Shigehara K, Nakata H, Takada S, Fukukawa K, Kato Y, Nakagawa T, Kawaguchi S, Izumi K, Mizokami A.	Viruses. 2025; 17(10):1304.
Remarkable Responses to Chemoimmunotherapy in Ultra-Rare Urachal Cancer: A Case Series and Reverse Translational Research.	Kotani H, Sato S, Shigehara K, Saito D, Sakaguchi H, Nishiyama A, Matsumoto I, Mizokami A, Yano S, Taniguchi H.	MedComm (2020). 2025; 6(12):e70516.
Durable Responses With Immune Checkpoint Inhibitors in the DANUBE Trial.	Nakagawa R, Izumi K, Mizokami A.	Int J Urol. 2025 ;32(12):1907-1909.
Comprehensive Genome Profiling Test in Japanese Patients With Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study	Hori T, Iwamoto H, Makino T, Naito R, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Izumi K, Mizokami A.	Cureus. 2025 Jan 11;17(1):e77300. doi: 10.7759/cureus.77300. eCollection 2025 Jan.
Development of Drug-resistant Cell Lines for Experimental Procedures	Kadomoto S, Shelley G, Mizokami A, Keller ET.	J Vis Exp. 2025 Aug 12;(222):10.3791/68957. doi: 10.3791/68957.
Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging	Iwamoto H, Izumi K, Mizokami A.	Int J Urol. 2025 May;32(5):540-541. doi: 10.1111/iju.70015. Epub 2025 Feb 17.
Fibroblast-specific palladin drives kidney fibrosis via MRTF-SRF signaling	Yamamoto N, Sakai N, Yamamura Y, Kaikoi D, Hayashi D, Matsuno T, Koshino A, Sako K, Horikoshi K, Yuasa T, Tamai A, Minami T, Oshima M, Nakagawa S, Kitajima S, Hara A, Shimizu M, Terakawa J, Horike SI, Daikoku T, Mizokami A, Ikeda H, Kadoguchi M, Arakawa H, Ohtsuki S, Lagares D, Wada T, Iwata Y.	J Pathol. 2025 Oct 24. doi: 10.1002/path.6485. Online ahead of print.
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study	Sazuka T, Tatsugami K, Shirotake S, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Kimura G, Onodera S, Yamaguchi K, Uemura H.	Int J Urol. 2025 Nov 25. doi: 10.1111/iju.70281. Online ahead of print.
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis	Matsubara N, Miyake H, Uemura H, Mizokami A, Kikukawa H, Kosaka T, Nishimura K, Nakamura M, Kobayashi K, Komaru A, Mori Y, Toyoizumi S, Hori N, Umeyama Y, Uemura H.	Cancer Med. 2025 Jan;14(1):e70333. doi: 10.1002/cam4.70333.
The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study)	Nishimoto K, Kimura G, Sazuka T, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Nagata M, Onodera S, Ito H, Uemura H.	Int J Urol. 2025 Aug;32(8):961-972. doi: 10.1111/iju.70076. Epub 2025 Apr 24.

一覧に戻る